Memphasys Ltd (MEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Memphasys Ltd (MEM) has a cash flow conversion efficiency ratio of -0.306x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.23 Million ≈ $-871.57K USD) by net assets (AU$4.02 Million ≈ $2.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Memphasys Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Memphasys Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MEM total liabilities for a breakdown of total debt and financial obligations.
Memphasys Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Memphasys Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Globe Kita Terang Tbk PT
JK:GLOB
|
-0.003x |
|
Scandinavian ChemoTech AB Series B
ST:CMOTEC-B
|
-0.550x |
|
Radiant Utama Interinsco Tbk
JK:RUIS
|
-0.070x |
|
Ostin Technology Group Co Ltd
NASDAQ:OST
|
-0.096x |
|
AUX Resources Corporation
V:AUX
|
-0.314x |
|
Burford Capital Limited
LSE:BUR
|
0.048x |
|
Impax Environmental Markets PLC
LSE:IEM
|
0.003x |
|
Indo Straits Tbk
JK:PTIS
|
0.048x |
Annual Cash Flow Conversion Efficiency for Memphasys Ltd (2008–2025)
The table below shows the annual cash flow conversion efficiency of Memphasys Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see Memphasys Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.37 Million ≈ $3.80 Million |
AU$-2.41 Million ≈ $-1.71 Million |
-0.449x | +5.01% |
| 2024-06-30 | AU$6.84 Million ≈ $4.84 Million |
AU$-3.23 Million ≈ $-2.29 Million |
-0.473x | -148.09% |
| 2023-06-30 | AU$7.38 Million ≈ $5.23 Million |
AU$-1.41 Million ≈ $-995.31K |
-0.190x | -567.12% |
| 2022-06-30 | AU$7.65 Million ≈ $5.41 Million |
AU$311.82K ≈ $220.63K |
0.041x | +685.09% |
| 2021-06-30 | AU$8.61 Million ≈ $6.09 Million |
AU$44.71K ≈ $31.63K |
0.005x | -57.84% |
| 2020-06-30 | AU$9.76 Million ≈ $6.90 Million |
AU$120.19K ≈ $85.05K |
0.012x | +110.57% |
| 2019-06-30 | AU$6.07 Million ≈ $4.30 Million |
AU$-707.47K ≈ $-500.58K |
-0.117x | +47.11% |
| 2018-06-30 | AU$3.35 Million ≈ $2.37 Million |
AU$-738.42K ≈ $-522.48K |
-0.220x | -107.21% |
| 2017-06-30 | AU$-402.24K ≈ $-284.61K |
AU$-1.23 Million ≈ $-869.31K |
3.054x | +455.22% |
| 2016-06-30 | AU$1.48 Million ≈ $1.05 Million |
AU$-1.27 Million ≈ $-899.02K |
-0.860x | +73.50% |
| 2015-06-30 | AU$746.59K ≈ $528.26K |
AU$-2.42 Million ≈ $-1.71 Million |
-3.244x | -442.08% |
| 2014-06-30 | AU$-992.85K ≈ $-702.50K |
AU$-941.64K ≈ $-666.27K |
0.948x | +771.03% |
| 2013-06-30 | AU$6.99 Million ≈ $4.95 Million |
AU$-987.97K ≈ $-699.05K |
-0.141x | +1.56% |
| 2012-06-30 | AU$4.56 Million ≈ $3.23 Million |
AU$-655.09K ≈ $-463.52K |
-0.144x | +40.80% |
| 2011-06-30 | AU$7.00 Million ≈ $4.95 Million |
AU$-1.70 Million ≈ $-1.20 Million |
-0.243x | -18.49% |
| 2010-06-30 | AU$12.84 Million ≈ $9.09 Million |
AU$-2.63 Million ≈ $-1.86 Million |
-0.205x | +79.64% |
| 2009-06-30 | AU$-398.47K ≈ $-281.94K |
AU$400.62K ≈ $283.46K |
-1.005x | +72.30% |
| 2008-06-30 | AU$1.10 Million ≈ $779.28K |
AU$-4.00 Million ≈ $-2.83 Million |
-3.630x | -- |
About Memphasys Ltd
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port… Read more